These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33791510)

  • 1. Size-Dependent Inhibitory Effects of Antibiotic Nanocarriers on Filamentation of
    Songkiatisak P; Ding F; Cherukuri PK; Xu XN
    Nanoscale Adv; 2020 May; 2(5):2135-2145. PubMed ID: 33791510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Size-Dependent Inhibitory Effects of Antibiotic Drug Nanocarriers against
    Ding F; Songkiatisak P; Cherukuri PK; Huang T; Xu XN
    ACS Omega; 2018 Jan; 3(1):1231-1243. PubMed ID: 29399654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic Drug Nanocarriers for Probing of Multidrug ABC Membrane Transporter of
    Cherukuri PK; Songkiatisak P; Ding F; Jault JM; Xu XN
    ACS Omega; 2020 Jan; 5(3):1625-1633. PubMed ID: 32010837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Susceptibilities of Escherichia coli, Salmonella and Staphylococcus aureus isolated from animals to ofloxacin and commonly used antimicrobial agents].
    Takahashi I; Yoshida T; Higashide Y; Sakano T
    Jpn J Antibiot; 1990 Jan; 43(1):89-99. PubMed ID: 2190017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibacterial activities of ofloxacin against recent isolates from patients with community-acquired infections].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1991 Sep; 44(9):941-57. PubMed ID: 1960856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial resistance modulation of MDR E. coli by antibiotic coated ZnO nanoparticles.
    Anwar MA; Aqib AI; Ashfaq K; Deeba F; Khan MK; Khan SR; Muzammil I; Shoaib M; Naseer MA; Riaz T; Tanveer Q; Sadiq M; Lodhi FL; Ashraf F
    Microb Pathog; 2020 Nov; 148():104450. PubMed ID: 32853679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antimicrobial activity of ofloxacin against recent clinical isolates from otitis media and otitis externa].
    Matsumoto Y; Suzuki Y; Ishii Y; Ishihara R; Nakazawa A; Nakane Y; Nishinari C; Deguchi K
    Jpn J Antibiot; 1998 Sep; 51(9):561-75. PubMed ID: 9846283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1986). I. Susceptibility distribution].
    Kosakai N; Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1989 Oct; 42(10):2141-73. PubMed ID: 2691714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibacterial activities of ofloxacin against recent clinical isolates from patients with ocular infections].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1993 May; 46(5):349-63. PubMed ID: 8326675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental study on the antituberculous activity of ofloxacins].
    Duan L; Liang G; Li H
    Zhonghua Jie He He Hu Xi Za Zhi; 1997 Apr; 20(2):98-100. PubMed ID: 10072834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An infection-resistant PTFE vascular graft; spiral coiling of the graft with ofloxacin-bonded PTFE thread.
    Okahara K; Kambayashi J; Shibuya T; Kawasaki T; Sakon M; Dohi Y; Oka Y; Ito S; Miyake S
    Eur J Vasc Endovasc Surg; 1995 May; 9(4):408-14. PubMed ID: 7633985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple robust method for synthesis of metallic copper nanoparticles of high antibacterial potency against E. coli.
    Chatterjee AK; Sarkar RK; Chattopadhyay AP; Aich P; Chakraborty R; Basu T
    Nanotechnology; 2012 Feb; 23(8):085103. PubMed ID: 22293320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro activities and pharmacokinetics/pharmacodynamics estimations of veterinary fluoroquinolones against avian pathogenic Escherichia coli isolates.
    Ozawa M; Baba K; Shimizu Y; Asai T
    Microb Drug Resist; 2010 Dec; 16(4):327-32. PubMed ID: 20624095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bacteriological evaluation of ofloxacin otic solution].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1992 Oct; 45(10):1342-55. PubMed ID: 1479686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of silver-carbon nanoparticles on the bacterial flora of bull semen.
    Yousef MS; Abdelhamid HN; Hidalgo M; Fathy R; Gómez-Gascón L; Dorado J
    Theriogenology; 2021 Feb; 161():219-227. PubMed ID: 33340755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aluminium-containing antacid on bioavailability of ofloxacin following oral administration of pivaloyloxymethyl ester of ofloxacin as prodrug.
    Maeda Y; Omoda K; Konishi T; Takahashi M; Kihira K; Hibino S; Tsukiai S
    Biol Pharm Bull; 1993 Jun; 16(6):594-9. PubMed ID: 8364513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of silver nanoparticles on zebrafish (Danio rerio) and Escherichia coli (ATCC 25922): a comparison of toxicity based on total surface area versus mass concentration of particles in a model eukaryotic and prokaryotic system.
    Bowman CR; Bailey FC; Elrod-Erickson M; Neigh AM; Otter RR
    Environ Toxicol Chem; 2012 Aug; 31(8):1793-800. PubMed ID: 22573570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
    Gómez-Lus R; Adrián F; del Campo R; Gómez-Lus P; Sánchez S; García C; Rubio MC
    Int J Antimicrob Agents; 2001 Jul; 18(1):49-54. PubMed ID: 11463526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytological and cytogenetic effects of the fluoroquinolone ofloxacin on human periodontal ligament fibroblasts.
    Someya T; Tamura Y; Tsutsui T
    J Periodontal Res; 2000 Dec; 35(6):352-60. PubMed ID: 11144408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of clinical efficacy of rokitamycin (RKM) and ofloxacin (OFLX) for the treatment of Campylobacter enteritis by a double-blind method. The Research Committee for the Effect of Rokitamycin, Research Group for Infectious Enteritis].
    Obana M; Tomizawa I; Takizawa Y; Nitta Y; Sagara H; Seo T; Sato J; Tsunoda T; Ota S; Machii A
    Kansenshogaku Zasshi; 1991 Sep; 65(9):1165-82. PubMed ID: 1761896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.